Related Experiment Video

Updated: Mar 30, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

Emmanuelle Le Ray1, Sundar Jagannath2, Antonio Palumbo3

  • 1a Hematology Department , CHU Cochin, Paris V René Descartes University , Paris , France.

Expert Review of Hematology
|November 13, 2015
PubMed

Insights

New targeted therapies offer improved outcomes for relapsed/refractory multiple myeloma (RRMM) patients. This review covers new proteasome inhibitors and immunotherapies for RRMM treatment.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Relapsed/refractory multiple myeloma (RRMM) outcomes have improved with proteasome inhibitors (PIs) and immunomodulatory drugs.
  • However, treatment resistance and limited efficacy remain challenges in managing multiple myeloma.
  • The incurable nature of multiple myeloma necessitates continuous development of novel therapeutic agents.

Purpose of the Study:

  • To provide an overview of recent advances in targeted therapy for RRMM.
  • To discuss newly approved agents and emerging treatment strategies.
  • To focus on monotherapy and combination targeted therapies for RRMM.

Main Methods:

  • Literature review of recent clinical trials and studies.
  • Analysis of data on novel oral PIs, immunotherapies (e.g., CD38- or SLAMF7-targeted antibodies), and small molecules.
  • Synthesis of information on efficacy and safety of targeted agents in RRMM.

Main Results:

  • Recent approvals include new oral PIs (ixazomib) and novel immunotherapies.
  • Combination targeted therapies show promise in overcoming drug resistance.
  • Ongoing research focuses on expanding treatment options for RRMM patients.

Conclusions:

  • Targeted therapies, including novel PIs and immunotherapies, represent significant progress in RRMM management.
  • Personalized treatment approaches combining targeted agents are crucial for improving patient outcomes.
  • Continued research and development are essential to address unmet needs in multiple myeloma therapy.
Keywords:
combination therapyimmunomodulatory drugsmonotherapyproteasome inhibitorsrelapsed/refractory multiple myeloma

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K